Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register
2011

Review of Naratriptan for Migraine Treatment

Sample size: 6120 publication 10 minutes Evidence: moderate

Author Information

Author(s): Tfelt-Hansen Peer Carsten

Primary Institution: Department of Neurology, Danish Headache Center, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark

Hypothesis

Is naratriptan effective for treating migraines compared to placebo and other medications?

Conclusion

Naratriptan 2.5 mg is effective for acute migraine treatment and has a tolerability profile similar to placebo.

Supporting Evidence

  • Naratriptan 2.5 mg was superior to placebo in 6 RCTs.
  • Naratriptan 1 mg b.i.d. showed some effect in short-term prophylaxis for menstruation-associated migraine.
  • Naratriptan 2.5 mg had a similar adverse effect profile to placebo.

Takeaway

Naratriptan helps people with migraines feel better, and it's as safe as taking a sugar pill.

Methodology

The review analyzed data from 17 double-blind, randomized, controlled trials found in the GSK Trial Register.

Potential Biases

The pharmaceutical company may have influenced the publication of results.

Limitations

Less than half of the trials were fully published, leading to potential publication bias.

Participant Demographics

The trials included a total of 6,112 patients, with varying demographics across multiple centers.

Statistical Information

P-Value

0.011

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s10194-011-0327-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication